ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP) - Takeaways - MDSpire

ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP)

  • By

  • Azza Ismail

  • Rosamaria Nitti

  • Basil Sharrack

  • Manuela Badoglio

  • Pascale Ambron

  • Myriam Labopin

  • Tobias Alexander

  • John A. Snowden

  • Raffaella Greco

  • August 14, 2024

  • 0 min

Share

  • 1

    Autologous HSCT is a standard treatment for severe autoimmune diseases, particularly for relapsing-remitting MS and early severe SSc.

  • 2

    EBMT guidelines recommend Cy-ATG and BEAM-ATG as preferred conditioning regimens, with ATG being widely used for T-cell depletion.

  • 3

    A survey of 46 EBMT centers revealed variability in serotherapy practices, with most centers using ATG and some combining it with rituximab.

  • 4

    Adverse effects from serotherapy are common, with centers using premedication to mitigate infusion-related reactions and other complications.

  • 5

    The survey highlighted the occurrence of disease-related symptoms during serotherapy, particularly in patients with neurological autoimmune diseases.

Original Source(s)

ATG and other serotherapy in conditioning regimens for autologous HSCT in autoimmune diseases: a survey on behalf of the EBMT Autoimmune Diseases Working Party (ADWP)

  • by Azza Ismail, Rosamaria Nitti, Basil Sharrack, Manuela Badoglio, Pascale Ambron, Myriam Labopin, Tobias Alexander, John A. Snowden, Raffaella Greco

  • August 14, 2024

Related Content

OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)

CAR T cells and T cell engagers for autoimmunity—lessons from hematology

CAR-T cell therapy embarks on autoimmune disease